Abstract 225P
Background
Prostate cancer ranges from indolent to aggressive, with 10–20% of patients developing metastases. Immune cell interactions in the tumor microenvironment facilitate growth. This study aimed to characterize circulating immune cells in patients with oligometastatic (OMPC) and plurimetastatic prostate cancer (PMPC).
Methods
This retrospective cohort study included individuals with metastatic prostate cancer (mPC). Patients were classified into two groups: OMPC (five or fewer lesions in bone and/or lymph nodes via CT or bone scans), and PMPC, those not meeting OMPC criteria. Demographic data and immune cell subsets were collected at admission. After blood collection, peripheral blood mononuclear cells were isolated, and flow cytometry assessed various immune populations (γδ T cells, αβ T cells, Tregs, memory T cells, effector T cells, NK cells, NKT cells, B cells, myeloid cells, and monocytes) and cytokines (TNF-α, IFN-γ, IL-17). The Mann–Whitney U test was used for comparisons, with p ≤ 0.05 considered significant.
Results
43 patients were identified, with a median age of 64 years (50-80). 17 patients (39.5%) had OMPC and 26 (60.5%) had PMPC. 16 patients (37.2%) presented with de novo mPC. Bone was the most common metastatic site in both groups. Most patients (67.4%, n=29) received hormone therapy (HT) as first-line treatment , while 9 patients (20.9%) received chemotherapy plus HT. An increase in γδ2+ T cells (p=0.048) was noted in the OMPC group. There was a trend toward increased levels of γδ2+ expressing IFN-γ (p=0.066) in PMPC patients.
Conclusions
A significant increase in γδ2+ T cells was observed in OMPC. These cells are critical for immune modulation. Elevated levels in OMPC subgroup may indicate an active immune response, potentially providing a protective effect against tumor progression in this subgroup. Conversely, PMPC patients showed a trend toward increased IFN-γ expression in γδ2+ T cells (p=0.066). While these cells can produce IFN-γ, those in OMPC may be less activated, limiting their effectiveness and suggesting an immune escape mechanism. This study has limitations; results are exploratory and require confirmation in a larger cohort. We plan to validate the differences in γδ2+ T cells and IFN-γ expression in an independent group.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
43P - Machine learning radiomics based on CT to predict response to lenvatinib plus tislelizumab based therapy for unresectable hepatocellular carcinoma
Presenter: Gang Chen
Session: Poster Display session
44P - Machine learning-based prediction of survival in patients with metastatic renal cell carcinoma receiving first-line immunotherapy
Presenter: Ahmed Elgebaly
Session: Poster Display session
45P - Gut microbiome signatures for exploring the correlation between gut microbiome and immune therapy response using machine learning approach
Presenter: Han Li
Session: Poster Display session
Resources:
Abstract
46P - Abnormal gut microbiota may cause PD-1 inhibitor-related cardiotoxicity via suppressing regulatory T cells
Presenter: Zeeshan Afzal
Session: Poster Display session
47P - Correlation of clinical, genetic and transcriptomic traits with PD-L1 positivity in TNBC patients
Presenter: Anita Semertzidou
Session: Poster Display session
48P - The A2AR antagonist inupadenant promotes humoral responses in preclinical models
Presenter: Paola Tieppo
Session: Poster Display session
49P - Highly potent novel armoured IL13Ra2 CAR T cell targeting glioblastoma
Presenter: Maurizio Mangolini
Session: Poster Display session
50P - Phase I trial of P-MUC1C-ALLO1 allogeneic CAR-T cells in advanced epithelial malignancies
Presenter: David Oh
Session: Poster Display session
51P - Unlocking CAR-T cell potential: Lipid metabolites in overcoming exhaustion in ovarian cancer
Presenter: Xiangyu Chang
Session: Poster Display session
Resources:
Abstract
52P - Tumor-targeted cytokine release by genetically-engineered myeloid cells rescues CAR-T activity and engages endogenous T cells against high-grade glioma in mouse models
Presenter: Federico Rossari
Session: Poster Display session